CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (150,712)	$ (144,187)	$ (128,832)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	40,413	39,777	31,848
Amortization of inventory step-up	0	901	9,826
Allowance for credit losses and inventory reserves	1,705	3,888	892
Share-based compensation	65,108	67,240	43,710
Amortization of discount and cost of issuance of debt	2,734	1,172	997
Asset impairment in relation to restructuring	3,607	998	0
Gain from change in fair value of warrants	0	0	(7,066)
(Gain) loss from change in fair value of contingent considerations and acquisition-related holdbacks	(6,970)	(29,041)	2,985
(Gain) loss from change in fair value of currency forward contract	(821)	1,650	850
Gain from extinguishment of debt	(2,623)	0	0
Deferred tax liabilities	(536)	(5,366)	(4,198)
Amortization of right-of-use assets	3,174	3,284	2,737
Other	0	0	14
Changes in operating assets and liabilities:
Accounts receivable	(2,861)	9,592	(32,199)
Inventory	2,524	(16,967)	(5,785)
Accounts payable	(7,737)	10,991	(1,697)
Accrued expenses and other current liabilities	1,155	3,539	(3,211)
Accrued payroll liabilities	152	(289)	(562)
Prepaid, other current and noncurrent assets	(1,094)	963	(10,298)
Operating lease liabilities	(3,071)	(2,934)	(2,500)
Other long-term liabilities	(1,277)	(3,812)	(1,896)
Net cash used in operating activities	(57,130)	(58,601)	(104,385)
Cash flows from investing activities:
Purchases of property and equipment	(14,294)	(14,337)	(12,752)
Payments for acquired software license	0	(1,722)	0
Business combinations, net of cash acquired	(17,673)	(3,200)	(94,990)
Net cash used in investing activities	(31,967)	(19,259)	(107,742)
Cash flows from financing activities:
Proceeds from issuance of common stock/At-the-market offering	0	19,847	53,136
Offering costs for the issuance of common stock/At-the-market offering	0	(428)	(1,138)
Wuxi EIP capital paid in	0	0	12,346
2029 convertible note capped call transactions	0	(23,380)	0
Proceeds from issuance of debt obligations	2,405	230,361	1,148
Issuance and debt discount costs related to debt obligations	(50)	(667)	0
Repurchase of debt obligations	(26,829)	0	0
Payments on debt obligations	(3,981)	(7,965)	(12,831)
Payments on financed software	(7,958)	(5,451)	(9,125)
Deferred payments on business combination	(2,534)	(3,036)	0
Proceeds from exercise of stock options	6	53	31
Net cash provided by (used in) financing activities	(38,941)	209,334	43,567
Effect of exchange rate changes on cash, and cash equivalents	(769)	1,396	(1,641)
Net increase (decrease) in cash and cash equivalents	(128,807)	132,870	(170,201)
Cash, cash equivalents, and restricted cash at beginning of period	284,548	151,678	321,879
Cash, cash equivalents, and restricted cash at end of period	155,741	284,548	151,678
Supplemental disclosure of cash flow information:
Cash paid for taxes	674	0	0
Cash paid for interest	15,048	7,435	7,421
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment, accrued but not paid	(460)	352	(300)
Fair value of common stock issued for investment in Expedera	0	3,428	0
Fair value of common stock issued for business combination	0	0	128,181
Fair value of common stock issued to satisfy contingent considerations and acquisition-related holdbacks	0	64,148	5,159
Fair value of common stock issuable for business combination	0	0	23,479
Contingent consideration for business combination	7,287	4,599	81,745
Accrual for purchase consideration for business combination	$ 2,970	$ 800	$ 800